Pazopanib fda approval date?

When did the FDA approve pazopanib (Votrient)?

Pazopanib (Votrient) received FDA approval on October 18, 2009. [1]

What was pazopanib first approved for?

FDA initially approved pazopanib for the treatment of advanced renal cell carcinoma (RCC). [1]

Related: when did the patent/exclusivity start affecting access?

If you’re looking at timing beyond the FDA approval date (for example, when exclusivity or patents could shift competition), DrugPatentWatch.com tracks relevant IP and filing timelines for branded pazopanib. [2]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022465
[2] https://www.drugpatentwatch.com/